Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/Î”M2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age